Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
20 Sep 2020
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Pathogenesis-based therapy safe, effective for porokeratosis

18 Jan 2020
4 facts about cholesterol and statin you may not know

Treatment with topical cholesterol/lovastatin is effective and well-tolerated for patients with porokeratosis, results of a recent study have shown.

This highlights the value of a pathogenesis-based therapy that replaces deficient end products and prevents accumulation of potentially toxic precursors, according to the investigators.

A series of five porokeratosis patients (one with disseminated superficial actinic porokeratosis, two with porokeratosis palmaris et plantaris disseminate and two with linear porokeratosis) was included in this study that sought to assess the efficacy of topical cholesterol/lovastatin in different variants of the disease.

Patients were genotyped prior to treatment initiation. Subsequently, they applied topical cholesterol/lovastatin twice daily to a unilaterally defined treatment area for a duration of up to 3 months. The investigators then evaluated the response and photographed the patients at every visit.

MVD and PMVK mutations were present in three and two patients, respectively. Treatment with topical cholesterol/lovastatin, but not cholesterol alone, led to a near complete clearance of disseminated superficial actinic porokeratosis lesions after 4 weeks of therapy and to moderate improvement of porokeratosis palmaris et plantaris disseminate lesions and linear porokeratosis lesions.

No adverse events were reported. The study, however, was limited by its case series design and its small sample size.

“Porokeratosis is associated with mevalonate pathway gene mutations,” the investigators explained, adding that therapeutic options are few and often have limited efficacy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
20 Sep 2020
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.